Abstract
Liposomal drug delivery systems (LDDS) have emerged as a highly effective approach to improve the therapeutic potential of a variety of drugs. These nanoscale vesicular structures have the ability to encapsulate both hydrophilic and hydrophobic drugs, enhancing their bioavailability, stability, and therapeutic efficacy. This review article provides a comprehensive overview of the current trends in liposomal drug delivery, focusing on recent advancements, challenges, and future perspectives. The use of liposomes for targeted drug delivery, controlled release, and site-specific therapy in various diseases such as cancer, infection, and inflammatory disorders is discussed. Additionally, the paper highlights ongoing research in overcoming the limitations of LDDS, including stability issues and the scaling-up process for commercial production.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.